ISR Articles

41. Top 5 Oral Dosage Forms By Expenditure 9/18/2021

    In Q2 2021, ISR asked 100 outsourcers of oral dose manufacturing to allocate the proportion of their company’s outsourced expenditure by dosage form. The data show that traditional tablets currently account for the largest proportion of spend, followed by controlled release tablets and immediate release tablets. However, respondents predict some of the current spend on tablets will shift to capsules five years from now. To learn more, follow the link to the Oral Dosage Forms Market Outlook report preview.

42. Outsourcing Drivers For Small Molecule Manufacturing 7/6/2021

    ISR’s recent survey of small molecule outsourcers found that the majority of respondents outsource for one of two reasons: for all of their manufacturing needs, or to augment their internal manufacturing capacity.

43. Manufacturing Expenditure By Activity 7/6/2021

    Learn about the competitive activities that clinical manufacturing sponsors spend the most money on, while gaining some insight into the clinical manufacturing market and where it’s heading.

     
44. Pandemic's Influence On Small Molecule API Outsourcing Risk Mitigation 6/14/2021

    ISR asked 121 outsourcers of small molecule API about how the pandemic has influenced risk mitigation strategies with regard to outsourcing. More than half said they plan to increase contingency planning.

45. Small Molecule Drug Substance Outsourcing 5/12/2021

    In Q4 2020, ISR asked 123 outsourcers of small molecule API about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated tactically (38%), but that is expected to shift to preferred providers (41%) over the next three years as more outsourcers’ companies establish preferred relationships.

46. Covid's Impact on Outsourced Small Molecule Manufacturing 4/16/2021

    In Q42020, ISR surveyed 249 sponsors who outsource small molecule manufacturing to learn if their company experienced outsourced manufacturing complications as a result of the Covid-19 pandemic. Small molecule drug substance outsourcers were slightly more likely to report complications than small molecule drug substance outsourcers, 45% vs 40%.

47. Small Molecule Drug Substance Outsourcing Drivers By Company Size 3/16/2021

    In Q42020, ISR surveyed 123 sponsors who outsource small molecule drug substance manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (68%) while sponsors from non-large pharma use CMOs for all manufacturing needs (79%). 

48. Customer Loyalty In Small Molecule API Manufacturing 1/15/2021

    In Q42020, ISR surveyed 123 sponsors who outsource small molecule API to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users and an industry average derived from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.

49. Reasons CDMOs Lose Oral Dose Manufacturing Bids 11/13/2020

    In Q2, 2019, ISR asked 101 respondents who outsource oral dose drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 30% of respondents’ votes.

50. Reasons CDMOs Lose Sterile Injectable Manufacturing Bids 11/13/2020

    In Q2 2019, ISR asked 101 respondents who outsource sterile injectable drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 25% of respondents’ votes..